Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwetz, V; Schnedl, C; Urbanic-Purkart, T; Trummer, C; Dimai, HP; Fahrleitner-Pammer, A; Putz-Bankuti, C; Christopher, KB; Obermayer-Pietsch, B; Pieber, TR; Dobnig, H; Amrein, K.
Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.
Osteoporos Int. 2017; 28(12):3347-3354
Doi: 10.1007/s00198-017-4190-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Amrein Karin
- Theiler-Schwetz Verena
- Co-Autor*innen der Med Uni Graz
- Dimai Hans Peter
- Dobnig Harald
- Fahrleitner-Pammer Astrid
- Obermayer-Pietsch Barbara
- Pieber Thomas
- Putz-Bankuti Csilla
- Schnedl Christian
- Trummer Christian
- Urbanic Purkart Tadeja
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In this post hoc analysis of the VITdAL-ICU study, an RCT in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml, vitamin D3 did not have a significant effect on β-Crosslaps and osteocalcin. Observational studies have shown accelerated bone loss in ICU survivors. A reversible contributor is vitamin D deficiency. In a post hoc analysis of the VITdAL-ICU study, we evaluated the effect of high-dose vitamin D3 on the bone turnover markers (BTM) β-Crosslaps (CTX) and osteocalcin (OC). The VITdAL-ICU study was a randomized, double-blind, placebo-controlled trial in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml who received placebo or high-dose vitamin D3 (a loading dose of 540,000 IU and starting 1 month after the loading dose five monthly maintenance doses of 90,000 IU). In this analysis on 289 survivors (209 telephone, 80 personal follow-up visits), BTM were analyzed on days 0, 3, 7, 28, and 180; self-reported falls and fractures were assessed. Bone mineral density (BMD) was measured after 6 months. At baseline, CTX was elevated; OC was low in both groups-after 6 months, both had returned to normal. There were no differences between groups concerning BTM, BMD, falls, or fractures. In linear mixed effects models, CTX and OC showed a significant change over time (p < 0.001, respectively), but there was no difference between the vitamin D and placebo group (p = 0.688 and p = 0.972, respectively). Vitamin D supplementation did not have a significant effect on BTM. Further studies should assess the effectiveness of vitamin D on musculoskeletal outcomes in ICU survivors.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Bone Density - drug effects
- Bone Density Conservation Agents - pharmacology
- Bone Density Conservation Agents - therapeutic use
- Bone Remodeling - drug effects
- Bone Remodeling - physiology
- Cholecalciferol - pharmacology
- Cholecalciferol - therapeutic use
- Collagen - blood
- Critical Illness - therapy
- Double-Blind Method -
- Female -
- Follow-Up Studies -
- Humans -
- Intensive Care Units -
- Male -
- Middle Aged -
- Osteocalcin - blood
- Peptide Fragments - blood
- Vitamin D - analogs & derivatives
- Vitamin D - blood
- Vitamin D Deficiency - blood
- Vitamin D Deficiency - drug therapy
- Vitamin D Deficiency - physiopathology
- Find related publications in this database (Keywords)
- Bone loss
- Bone mineral density
- Bone turnover markers
- Critical illness
- Fracture
- Long-term outcomes
- Osteoporosis
- Vitamin D3